Emerging Treatment Options in Inflammatory Bowel Disease
In Collaboration With
Original Article Reference
This SciPod is a shortened and simplified summary of ‘Emerging Treatment Options in Inflammatory Bowel Disease’, published by Karger Publishers https://doi.org/10.1159/000507782
The complete original works are available at www.karger.com
Share Episode
About this episode
Inflammatory bowel disease (IBD) is a group of gastrointestinal conditions affecting almost 7 million people globally, and this incidence is rising. While treatments have improved over the last century, many patients do not respond sufficiently, especially those with moderate to severe levels of the disease. Novel drugs that restrain the immune system and reduce inflammation are being developed with the hope of improving patient outcomes. Dr Benjamin Misselwitz at Island Hospital of Bern and Bern University and his colleagues have conducted a comprehensive review of the emerging therapies and make recommendations for improving treatment for a wider range of patients.
This work is licensed under a Creative Commons Attribution 4.0 International License. 
What does this mean?
Share: You can copy and redistribute the material in any medium or format
Adapt: You can change, and build upon the material for any purpose, even commercially.
Credit: You must give appropriate credit, provide a link to the license, and indicate if changes were made.
Related episodes
Professor Lobelia Samavati | Paving the Way for Antibody-based Diagnostics for Tuberculosis and Sarcoidosis
Tuberculosis – or TB – is a global health threat, with 10 million new cases annually. Diagnosing TB can be a challenge, as there is a lack of rapid, point-of-care diagnostic tests. It can also be difficult to distinguish between TB and other inflammatory diseases, such as Sarcoidosis. One option may be to identify antibodies in patient samples that can reveal the presence of TB. However, current antibody tests for TB lack accuracy. Professor Lobelia Samavati and colleagues at the Wanye State University School of Medicine in Michigan are tackling this challenge to cast light on the immune signature of these diseases. Their aim is to develop new diagnostic techniques for TB and Sarcoidosis.
Dr Abayomi Sanusi | Can Faith Institutions Encourage People to Maintain Healthy Blood Pressure?
High blood pressure, also known as hypertension, is a common and potentially dangerous condition that increases the risk of many severe medical issues, including heart disease, heart attack, stroke, heart failure, and kidney disease. Dr Abayomi Sanusi, a researcher at the University of York, recently carried out a study exploring how faith-based institutions could encourage their community members to adopt healthy behaviours that can reduce hypertension.
Ria Nishikawara | Exploring How to Improve Healthcare for Patients with Fibromyalgia
Fibromyalgia is a relatively common and yet poorly understood condition characterised by chronic diffuse pain and stiffness, chronic fatigue, poor sleep and cognitive difficulties. Ria Nishikawara at the University of British Columbia and her collaborators Dr Izabela Schultz, Dr Lee Butterfield, and John Murray, carried out a study exploring the unique healthcare experiences of patients diagnosed with fibromyalgia. Their aim was to determine what patients found most helpful and how the available services could be improved.
Addressing antimalarial drug resistance in Africa to ensure patients can continue to be saved
We are pleased to be joined by Dorothy Achu, Regional Malaria Adviser, WHO African Region; Aimable Mbituyumuremyi, Director, National Malaria Control Program, Ministry of Health, Rwanda; Adam Aspinall, Senior Director, Access and Product Management, and George Jagoe, Executive Vice-President Medicines for Malaria Venture. To learn about antimalarial drug resistance in Africa to ensure patients can continue to be saved.